Final CMS Aducanumab Decision Limits Coverage to Clinical Trials

In a final decision on the funding of the controversial Alzheimer’s drug aducanumab (Aduhelm), federal officials largely stuck to their draft plan to limit Medicare payment to patients enrolled in clinical trials. On Thursday, the Centers for Medicare and Medicaid Services (CMS) released its national coverage determination (NCD) for funding aducanumab, and other anticipated similar … Read more

High Praise, Condemnation for CMS Aduhelm Coverage Plan

Medicare has received a key endorsement of its plan to restrict payment for the controversial Alzheimer’s disease (AD) drug aducanumab (Aduhelm) — but also drew pleas from other groups for more generous reimbursement of the drug, as well as expected similar medications currently in development . The Centers for Medicare & Medicaid Services (CMS) received … Read more